Vomiting News and Research

RSS

Vomiting is the process the body uses to eject some or all of the contents of the stomach through the mouth.

Afatinib ‘first line’ for advanced mutation-positive lung cancer

Afatinib should be given as a first-line treatment for Asian patients with advanced, epidermal growth factor receptor mutation-positive, non-small-cell lung cancer, researchers recommend.

17 Feb 2014

Hospi receives FDA clearance for Macy Catheter

Hospi Corporation, a privately-held medical device company focused on nurse invented products that optimize patient care, today announced receipt of 510(k) clearance from the U.S. Food and Drug Administration for its first product, the Macy Catheter. The Macy Catheter is the only device designed and approved solely for ongoing rectal delivery of medications and liquids.

13 Feb 2014

Researchers offer new options for men whose prostate cancer has spread to bones

Dartmouth-Hitchcock Norris Cotton Cancer Center has treated three men with a recently FDA-approved treatment, which offers new options for men whose prostate cancer has spread to their bones.

13 Feb 2014

Mallinckrodt's subsidiary to acquire all outstanding shares of Cadence Pharmaceuticals

Mallinckrodt plc, a leading global specialty pharmaceuticals company, and Cadence Pharmaceuticals, Inc. today announced that they have entered into a definitive agreement under which a subsidiary of Mallinckrodt plc will commence a tender offer to acquire all outstanding shares of Cadence Pharmaceuticals, Inc. for $14.00 per share in cash or approximately $1.3 billion on a fully diluted basis, which represents a 32% premium to the trailing 30-trading-day volume weighted average price (VWAP) of $10.62 per share for Cadence Pharmaceuticals, Inc.

11 Feb 2014

KKH doctors develop novel DIVA System for blood pressure management

New trial results1 have shown that the world's first Double Intravenous Vasopressor Automated (DIVA) System affords superior control of maternal blood pressure in women undergoing caesarean section under spinal anaesthesia, when compared with manually-administered medication to manage reduced blood pressure (vasopressor).

10 Feb 2014

Sarepta Therapeutics reports positive safety results from AVI-7288 Phase I study

Sarepta Therapeutics, Inc., a developer of innovative RNA-based therapeutics, today announced positive safety results from a Phase I multiple ascending dose study of AVI-7288 in healthy volunteers.

10 Feb 2014

Pfizer and Merck join forces to explore therapeutic potential of anti-PD-1 therapy

Pfizer Inc. announced today that it has agreed with Merck & Co., Inc., known as MSD outside the United States and Canada ("Merck"), through two Merck subsidiaries, to explore the therapeutic potential of Merck's investigational anti-PD-1 therapy, MK-3475, in combination with two Pfizer oncology assets.

5 Feb 2014

New American Cancer Society report calls diagnosis of childhood cancer

A new report from the American Cancer Society outlines progress made and -more importantly-challenges that remain in fighting childhood cancer. The report estimates the number of new cancer cases and deaths for children and adolescents in the United States, summarizes the most recent and comprehensive data on cancer incidence, mortality, and survival, and outlines what is known and where answers are still needed for childhood cancers.

31 Jan 2014

Pfizer announces results from Phase 3 study of ALO-02 in patients with chronic low back pain

Pfizer Inc. (NYSE: PFE) announced today top-line results from a Phase 3 study of investigational agent ALO-02 (oxycodone hydrochloride and naltrexone hydrochloride extended-release capsules) in patients with moderate-to-severe chronic low back pain.

24 Jan 2014

Scientists to decode intestinal disease bacteria using genome sequencing technologies

The University of Liverpool is to decipher the genomes of the UK's main bacterial cause of food poisoning which results in over 21,000 hospital admissions and 100 deaths each year.

22 Jan 2014

Alexion's Soliris gets FDA orphan drug designation for DGF prevention in renal transplant patients

Alexion Pharmaceuticals today announced that the U.S. Food and Drug Administration has granted an orphan drug designation to Soliris (eculizumab), a first-in-class terminal complement inhibitor, for the prevention of delayed graft function in renal transplant patients.

21 Jan 2014

Dihydroartemisinin-piperaquine more effective than artemether-lumefantrine in treating malaria

'Dihydroartemisinin-piperaquine is more effective than artemether-lumefantrine, and has fewer side effects than artesunate-mefloquine' concludes a systematic review published by the Cochrane Infectious Disease Group, hosted by LSTM.

21 Jan 2014

State highlights: Battle over jail medical care in Texas jails; Medicaid coverage for inmates; N.C. docs sue over Medicaid billing system

In November, David Conis Jr. sat in a Henderson County courtroom, vomiting repeatedly because of his vacillating blood-sugar levels, terrified that he was facing a diabetic coma. ... Henderson County state district Judge Carter Tarrance, concerned that the county jail was not providing adequate care, sent Conis to a local clinic and ordered the jail to follow the doctor's instructions (Grissom, 1/17).

20 Jan 2014

$Japanese MHLW approves ADCETRIS for relapsed or refractory CD30-positive HL and ALCL$

Japanese MHLW approves ADCETRIS for relapsed or refractory CD30-positive HL and ALCL

Seattle Genetics, Inc. today announced that its collaborator, Takeda Pharmaceutical Company Limited, has received approval of ADCETRIS (brentuximab vedotin) from the Japanese Ministry of Health, Labour and Welfare for the treatment of patients with CD30-positive relapsed or refractory Hodgkin lymphoma and anaplastic large cell lymphoma.

18 Jan 2014

Researchers find difficult to kill Salmonella biofilms with three types of disinfectant

Once Salmonella bacteria get into a food processing facility and have an opportunity to form a biofilm on surfaces, it is likely to be extraordinarily difficult, if not impossible, to kill it, according to research published ahead of print in the journal Applied and Environmental Microbiology.

17 Jan 2014

Heritage announces availability of Prochlorperazine Edisylate Injection

Heritage Pharmaceuticals Inc. announced the immediate availability of Prochlorperazine Edisylate Injection in the 5mg/mL strength.

16 Jan 2014

FDA accepts Iroko Pharmaceuticals' ZORVOLEX sNDA for review

Iroko Pharmaceuticals, LLC, a global specialty pharmaceutical company dedicated to advancing the science of analgesia, announced that the U.S. Food and Drug Administration has accepted for review the Supplemental New Drug Application for ZORVOLEX (diclofenac), a lower dose nonsteroidal anti-inflammatory drug, for the proposed indication of treatment of osteoarthritis pain in adults. ZORVOLEX was approved by FDA in October 2013 for the treatment of mild to moderate acute pain in adults.

15 Jan 2014

Study questions widely used method of diagnosing acute mountain sickness

A study led by University of British Columbia scientists calls into question a widely used method of diagnosing acute mountain sickness.

9 Jan 2014

GSK receives FDA approval for combination of Mekinist with Tafinlar for treatment of melanoma

GlaxoSmithKline plc announced today that the U.S. Food and Drug Administration (FDA) has approved Mekinist® (trametinib) for use in combination with Tafinlar® (dabrafenib) for the treatment of patients with unresectable melanoma (melanoma that cannot be removed by surgery) or metastatic melanoma (melanoma which has spread to other parts of the body) with BRAF V600E or V600K mutations.